About The Homocystinurias Data Collection Program
The HCU Networks have partnered with RARE-X to drive a Data Collection Program for the homocystinurias. The RARE-X platform enables the gathering, structuring and sharing of critical patient data at scale. This patient data will help accelerate research, drive disease understanding and enable the development of new diagnostic tools and future treatments and cures.
To learn how your participation in a Data Collection Program can accelerate research and drive the development of future treatments and cures visit here.
The HCU Networks are building the Homocystinurias Data Collection Program to:
- Inform researchers how homocystinurias impact patients and change over time
- Enable better data to use in drug development and clinical trials
- Give patients the opportunity to participate in clinical trials
- Reduce the time it takes to study new medicines
- Accelerate the time to get treatments to patients
- Enable the use of data as a placebo (instead of actual patients) in a clinical trial
Privacy and Security for Patient Data Collection
The Homocystinurias Data Collection Program is patient-owned and enabled by RARE-X technology. All data governance, consent support, and data security are delivered by RARE-X. Privacy is something RARE-X takes seriously and patient names are never revealed. View the steps Rare-X takes to ensure patient privacy and security here.
About RARE-X
RARE-X is a 501(c)(3) non-profit created by leaders in the fields of patient advocacy, medical research, biopharma, and technology.
RARE- X is collaborating with rare disease communities, to apply technology proven in other large-scale public health and genomic data-sharing initiatives to support researchers developing treatments for rare disease patients.
RARE-X is leveraging existing technology powered by the Broad Institute of MIT and Harvard, which will support patients (in data collection, structuring and responsible sharing), clinicians (in accelerating diagnosis and improving and tracking health outcomes), researchers and biopharma (with the data they need to identify, develop and track the impact of breakthrough treatments and cures).
